Motolimod

Motolimod

CAT N°: 22952
Price:

From 49.00 41.65

Motolimod is an agonist of toll-like receptor 8 (TLR8).{36954} It increases the production of TNF-? and IL-12 in human peripheral blood mononuclear cells (PBMCs; EC50s = 140 and 120 nM, respectively), monocytes, and myeloid dendritic cells. Motolimod also increases IFN-? production in natural killer (NK) cells and increases cytolysis in K562 NK cell-sensitive leukemia cells when used at concentrations of 167 and 500 nM for 48 hours. It increases plasma levels of a group of human cytokines, including IL-6, IL-12p70, TNF-?, MCP-1, and MIP-1?, in NOD-scid IL2rynull (NSG) mice reconstituted with human immune system (NSG-HIS) when administered at doses of 1.5 and 15 mg/m2.{36953} Motolimod, when used in combination with pegylated liposomal doxorubicin (PLD), reduces tumor growth and increases tumor infiltration of monocytes and T cells in an ovarian cancer NSG-HIS mouse model.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-amino-N,N-dipropyl-8-[4-(1-pyrrolidinylcarbonyl)phenyl]-3H-1-benzazepine-4-carboxamide
  • Correlated keywords
    • 1345249-66-2 1370046-37-9 VTX2337 VTX 378 VTX378 TLR-8 TNF? IL12 IFN? K562NK K-562NK K-562-NK IL6 IL-12p-70 IL-12p70 MCP1 MIP1? NODscid IL-2rynull NSGHIS interleukin
  • Product Overview:
    Motolimod is an agonist of toll-like receptor 8 (TLR8).{36954} It increases the production of TNF-? and IL-12 in human peripheral blood mononuclear cells (PBMCs; EC50s = 140 and 120 nM, respectively), monocytes, and myeloid dendritic cells. Motolimod also increases IFN-? production in natural killer (NK) cells and increases cytolysis in K562 NK cell-sensitive leukemia cells when used at concentrations of 167 and 500 nM for 48 hours. It increases plasma levels of a group of human cytokines, including IL-6, IL-12p70, TNF-?, MCP-1, and MIP-1?, in NOD-scid IL2rynull (NSG) mice reconstituted with human immune system (NSG-HIS) when administered at doses of 1.5 and 15 mg/m2.{36953} Motolimod, when used in combination with pegylated liposomal doxorubicin (PLD), reduces tumor growth and increases tumor infiltration of monocytes and T cells in an ovarian cancer NSG-HIS mouse model.

We also advise you